Key Takeaways
Johnson & Johnson's fiscal year 2025 (calendar year ended December 31, 2025) was the second full year as a pharmaceutical and medical technology company following the August 2023 spinoff of Kenvue (the former Consumer Health segment containing Tylenol, Band-Aid, Listerine, Neutrogena, and dozens of other consumer healthcare brands), which transformed Johnson & Johnson from a diversified three-segment conglomerate into a focused biopharma + medtech enterprise: revenue of approximately $90-92B (+5-7% YoY) was generated by the Innovative Medicine pharmaceutical segment (~$57-58B, 63% of revenue) and the MedTech segment ($33-34B, ~37%), with adjusted EPS of approximately $10.50-11.00 on approximately 2.4B diluted shares supporting Johnson & Johnson's status as the longest-tenured S&P 500 dividend aristocrat (62 consecutive annual dividend increases as of FY2025) and one of only two US public companies maintaining AAA credit ratings (alongside Microsoft). The pharmaceutical revenue mix is at a critical transition point: the Stelara (ustekinumab) franchise — which generated peak revenues of approximately $10.9B in FY2023 treating psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis — has begun the multi-year biosimilar erosion process that began with the late-2024 launch of biosimilar competitors in the US market and is projected to compress Stelara revenue from approximately $9.0B in FY2025 toward approximately $4-5B by FY2027 as biosimilar penetration accelerates; this Stelara erosion has been substantially offset through FY2024-FY2025 by accelerating growth in Darzalex (multiple myeloma, approximately $13B FY2025 revenue), Tremfya (psoriasis/IBD, approximately $5B FY2025), Erleada (prostate cancer, approximately $3.5B FY2025), and other growth franchises that demonstrate the depth of Johnson & Johnson's pharmaceutical pipeline. The MedTech segment underwent its own transformation through the cardiovascular acquisitions of Abiomed ($16.6B in 2022) and Shockwave Medical ($13.1B closed May 2024), which together created a leading position in interventional cardiology, electrophysiology, and structural heart procedures. The investment thesis for Johnson & Johnson in FY2026 centers on three structural questions: (1) whether the Innovative Medicine pipeline (Tremfya IBD label expansion, Rybrevant + lazertinib in EGFR-mutated lung cancer, Carvykti CAR-T expansion, Erleada label expansions, plus 70+ pipeline assets) generates the new product growth required to offset Stelara erosion sustainably, (2) whether the Talc litigation overhang resolves through the LTL Management Phase 3 bankruptcy strategy or alternative settlement approach, and (3) whether MedTech segment growth accelerates as Shockwave integration completes and the cardiovascular vertical scales as a meaningful margin contributor.
Johnson & Johnson was founded in 1886 in New Brunswick, New Jersey by the Johnson brothers as a producer of antiseptic surgical dressings and medical supplies, evolving over 140 years into the world's largest healthcare company by various measures (market capitalization, employees, geographic reach) until the 2023 Kenvue spinoff focused the corporate identity on prescription drugs and medical devices. CEO Joaquin Duato, who assumed the role in 2022 after a decade leading the pharmaceutical segment as Worldwide Chairman of Pharmaceuticals, oversaw the Kenvue spinoff (2023), the Abiomed and Shockwave acquisitions (2022/2024), and the multi-year strategic positioning that emphasized Johnson & Johnson's pharmaceutical and medical technology leadership rather than the diversified conglomerate model. The strategic identity that distinguishes post-spin Johnson & Johnson from pure-play pharmaceutical peers (Pfizer, Merck, AbbVie, Novartis) is the diversification across pharmaceutical and medical device end markets — providing earnings stability through the natural counter-cyclicality of drug pipeline transitions and medical device capital expenditure cycles. The strategic identity that distinguishes Johnson & Johnson from medical device pure-plays (Medtronic, Stryker, Boston Scientific) is the pharmaceutical earnings scale that funds R&D investment ($22-24B annually) at levels few medtech companies can match.
Business Structure
Johnson & Johnson operates through two primary business segments since the August 2023 Kenvue spinoff.
Innovative Medicine (~$57-58B revenue, ~$24-26B operating income): The pharmaceutical segment focused on six therapeutic areas:
- Immunology (~$17-18B revenue): Stelara (ustekinumab — psoriasis, IBD, currently in biosimilar erosion), Tremfya (guselkumab — psoriasis/IBD, growth franchise), Remicade (legacy biosimilar-eroded TNF inhibitor), Simponi/Simponi Aria (TNF inhibitor).
- Oncology (~$22-24B revenue): Darzalex (multiple myeloma, largest single product), Erleada (prostate cancer), Imbruvica (50/50 partnership with AbbVie, declining), Zytiga (legacy prostate, generic erosion), Carvykti (CAR-T multiple myeloma — partnership with Legend Biotech), Rybrevant + lazertinib (EGFR-mutated lung cancer launching 2024-2025).
- Neuroscience (~$8-9B revenue): Spravato (treatment-resistant depression, growth franchise), Concerta (legacy ADHD), Invega line (psychiatric).
- Pulmonary Hypertension (~$4-5B revenue): Opsumit, Uptravi (acquired through Actelion).
- Cardiovascular & Metabolism (~$2-3B revenue): Xarelto (anticoagulant, royalty from Bayer partnership).
- Infectious Diseases & Vaccines (~$2-3B revenue): post-COVID vaccine wind-down; HIV, RSV.
MedTech (~$33-34B revenue, ~$7-8B operating income): The medical device segment operates through four franchise areas:
- Cardiovascular (~$10-11B revenue): Acquired Abiomed (Impella heart pumps, $16.6B 2022) and Shockwave Medical (intravascular lithotripsy, $13.1B closed May 2024). Heart pumps + electrophysiology (Biosense Webster) + intracardiac imaging.
- Surgery (~$10-11B revenue): Ethicon (energy devices, sutures, mechanical staplers), Mentor (breast implants), Acclarent (ENT). Strategic robotic surgery platform under development (Ottava — late-stage development; not yet commercially launched at scale).
- Vision (~$5B revenue): Acuvue contact lenses, surgical lenses, dry eye products, refractive surgery (acquired AMO 2017).
- Orthopaedics (~$8-9B revenue): DePuy Synthes — joint reconstruction (knees, hips, shoulders), trauma, spine, sports medicine, craniomaxillofacial.
Key Core Metrics Performance
Revenue, Operating Income, and EPS Trajectory (FY2021–FY2025)
| Fiscal Year | Revenue (cont. ops post-Kenvue) | Adj. Operating Income | Adj. EPS | Free Cash Flow | Diluted Shares |
|---|---|---|---|---|---|
| FY2021 | ~$83.5B (incl. Consumer) | ~$28.0B | ~$9.80 | ~$20.0B | ~$2.65B |
| FY2022 | ~$87.0B (incl. Consumer) | ~$29.5B | ~$10.20 | ~$17.5B | ~$2.65B |
| FY2023 | ~$71.6B (post-Kenvue partial) | ~$26.3B | ~$10.07 | ~$22.0B | ~$2.55B |
| FY2024 | ~$88.8B (full post-Kenvue) | ~$28.9B | ~$10.65 | ~$19.5B | ~$2.45B |
| FY2025 | ~$91B | ~$30B | ~$10.85 | ~$20B | ~$2.40B |
Adjusted EPS growth approximately 2-3% annually post-Kenvue spinoff reflects the Stelara biosimilar erosion offsetting growth franchises — a transitional period before the next pharmaceutical growth cycle materializes from the FY2024-FY2027 launches.
Innovative Medicine Top Products (FY2025 estimate)
| Product | Therapeutic Area | FY2024 Revenue | FY2025 Revenue | Trajectory |
|---|---|---|---|---|
| Darzalex | Multiple myeloma | ~$11.7B | ~$13.0B | +11% growth (subcutaneous formulation expanding) |
| Stelara | Immunology (PsA, Crohn's, UC) | ~$10.4B | ~$9.0B | Biosimilar erosion launched late 2024 |
| Tremfya | Immunology (PsO, IBD label expansion) | ~$3.7B | ~$5.0B | +35% growth, Crohn's/UC expanding |
| Erleada | Prostate cancer | ~$2.8B | ~$3.5B | +25% growth |
| Imbruvica | CLL (50/50 with AbbVie) | ~$3.2B | ~$2.6B | Declining (pirtobrutinib competition) |
| Spravato | Treatment-resistant depression | ~$1.0B | ~$1.4B | +40% growth |
| Carvykti | CAR-T multiple myeloma | ~$1.0B | ~$2.0B | Capacity-driven ramp |
| Rybrevant + lazertinib | EGFR lung cancer | ~$0.4B | ~$1.5B | Newly launched MARIPOSA combo |
The Stelara biosimilar erosion of approximately -$1.4B revenue in FY2025 was offset by approximately +$2.5-3.0B in growth from Darzalex, Tremfya, Erleada, Carvykti, and Rybrevant — demonstrating the depth of the pharmaceutical pipeline that supports continued growth despite individual franchise losses.
MedTech Cardiovascular Reshape
| Period | MedTech Revenue | Cardiovascular Sub-segment | Cardiovascular Composition |
|---|---|---|---|
| FY2022 | ~$27.4B | ~$2.0B | Biosense Webster only |
| FY2023 | ~$30.4B | ~$5.5B | + Abiomed (full year) |
| FY2024 | ~$31.9B | ~$7.5B | + Shockwave (partial year, May close) |
| FY2025 | ~$34B | ~$10-11B | Shockwave full year |
The cardiovascular sub-segment growing from approximately $2B to approximately $10-11B in three years through M&A reflects Johnson & Johnson's strategic emphasis on this end-market — interventional cardiology and structural heart procedures growing 8-12% annually with favorable demographic (aging population) and reimbursement (procedure-based) dynamics.
Market Evaluation
Johnson & Johnson trades at approximately 13-16x forward adjusted EPS — value-leaning multiples that reflect both the AAA credit quality and dividend aristocrat status (positive durability factors) and the Stelara biosimilar erosion plus Talc litigation overhang (compressing factors). The bull case is pharmaceutical pipeline conversion + MedTech cardiovascular scale: if the FY2024-FY2027 launches (Tremfya IBD, Rybrevant lung cancer, Carvykti expansion, Erleada label expansions, Spravato continued growth) collectively offset the Stelara $5-6B erosion and add net $4-6B revenue by FY2027, and if MedTech cardiovascular reaches $13-14B with margin expansion as Shockwave scales, total revenue could reach $98-105B with adj. EPS approaching $12-13 — supporting equity at sustained 14-16x multiples. The bear case is pipeline disappointment + Talc resolution materially worse than expected: if Tremfya IBD penetration disappoints (Skyrizi from AbbVie taking dominant share), if Rybrevant lung cancer launch encounters competitive pressure (osimertinib continues dominating EGFR lung cancer), or if Talc litigation settles at the $20B+ range some plaintiffs' attorneys advocate (versus the $9-10B Johnson & Johnson currently provisions), EPS growth could remain in the 1-3% range with limited multiple expansion runway.
Talc Litigation Strategy and Pipeline Innovation Cadence
The most distinctive ongoing legal challenge for Johnson & Johnson is the talc litigation — approximately 60,000+ pending lawsuits alleging that asbestos contamination in Johnson & Johnson talc-based baby powder and Shower-to-Shower products caused ovarian cancer and mesothelioma in users. Johnson & Johnson denies the asbestos contamination claims and disputes the scientific causation, but has been pursuing a unique legal strategy of attempting to resolve the litigation through bankruptcy of a subsidiary (LTL Management LLC) created specifically to hold the talc liabilities. The first two LTL bankruptcy filings (2021 and 2023) were dismissed by federal courts on grounds that LTL was not in genuine financial distress. A third filing (2024-2025) using a different legal structure is currently in proceedings; if successful, it would establish a trust funded by approximately $9-10B from Johnson & Johnson to settle all current and future talc claims.
The strategic outcome matters meaningfully for the equity: a successful Phase 3 LTL bankruptcy would resolve approximately 60,000 pending cases for approximately $9-10B (which Johnson & Johnson has substantially provisioned) and end the ongoing legal cost and reputational drag. An unsuccessful Phase 3 outcome would force Johnson & Johnson to either litigate cases in conventional tort proceedings (where individual jury verdicts have ranged from $0 to $4.7B in single cases, creating massive financial uncertainty) or pursue alternative settlement frameworks at potentially much higher cost ($15-25B range possible based on plaintiffs' demand patterns).
The pipeline innovation cadence beyond the FY2024-FY2027 launches that drive the near-term thesis includes early-stage assets in immunology (additional psoriasis/IBD biologics), oncology (CAR-T expansion to additional indications, bispecific antibodies, antibody-drug conjugates), neuroscience (Spravato label expansion, additional psychiatric assets), and cardiovascular medicine (drug-device combination products leveraging the Shockwave + Abiomed platforms). Johnson & Johnson's historical innovation cadence — approximately 4-6 meaningful new molecular entity launches per decade — has supported the consistent revenue growth that funds the dividend aristocracy; the FY2026-FY2030 pipeline depth is strong enough to suggest this cadence continues into the next decade.